Whilst covalent Bruton’s tyrosine kinase (BTK) inhibitor therapy improves outcomes in chronic lymphocytic leukemia (CLL), resistance and adverse effects limit their long-term use. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.